- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03235037
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
Study Overview
Detailed Description
Angelman syndrome (AS) is a well-recognized cause of disability in children who present with movement or balance disorder, usually ataxia and/or tremulous movement of the limbs, severe speech and cognitive delay behavior disorders and was initially described by Harry Angelman as the " happy puppet syndrome" due to their disposition. Seizures, abnormal sleep-wake cycles and distinctive facial features have been also commonly seen. This disorder is almost exclusively diagnosed in childhood but adults have been reported. Angelman syndrome affects an estimated 1 in 12,000 to 20,000 people. Many of the characteristic features are caused by the loss of function of maternally inherited UBE3A allele on chromosome 15q11-q13 locus. Several different genetic mechanisms can cause loss of function of maternally inherited UBE3A gene. Majority of AS is caused by deletion of chromosome 15q11.2-q13 (approximately 70%), 11% is caused by a mutation in maternal copy of UBE3A. Paternal uniparental disomy (pat UPD) occurs in 7%. Rarely, a defect in imprinting region and chromosome rearrangement can also lead to AS.
Ubiquitin-protein ligase E3A (UBE3A) is involved in protein degradation through the ubiquitin proteasome pathway and displays predominantly in human fetal brain and adult frontal cortex. UBE3a is essential in the regulation of GTP cyclohydrolase I, an essential enzyme in dopamine biosynthesis. Knockout mouse studies have evaluated dopamine dependent behaviors as well as dopamine synthesis, content and release in the mesolimbic and nigrostriatal pathway of AS model mice. Impairment of UBE3A results in the accumulation of protein substrate and is also associated with a loss of dopaminergic neuronal function which plays a role in the clinical symptomatology. AS ( knockout) mice were reported to have maternal deficiency of Ube3a with reduced dopamine cell number in the substantia nigra pars compacta ((basal ganglia) . They demonstrated motoric and cognitive deficits. There are several mouse models that have demonstrated both the disorder and the beneficial effect of L dopa in the knockout mouse providing a basis for clinical human trials.
To date the primary treatment of children with Angelman syndrome has been only supportive and symptomatic such as physical, occupation and speech therapies, melatonin and Benadryl for insomnia and the treatment of seizure disorders. Little attention or success has been directed to the primary gait disturbance, namely ataxia and the cognitive impairment including processing, attention and speech delays which are cardinal features of the disorder.
In 2001, Harbord has reported two adults with Angelman syndrome and Parkinson's disease who had a positive response to L Dopa constituting the first report of the use of levodopa in Angelman syndrome.
Pediatric neurotransmitter disorders have previously been recognized involving the dopamine pathway. In the past investigators have reported on the distinct developmental and behavioral profile, cognitive deficits, motor and language skills utilizing standardized testing in the NIH Rare Disease Clinical Research Network, Angelman Rett collaborative.
This study will look at the effects of L Dopa on motor control including ataxia, cognitive function and developmental milestones in subjects with Angelman syndrome.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Angelman syndrome confirmed by molecular genetic testing.
- Age between 18 months and 16 years of age
- Absence of any contraindication to the use of Sinemet as determined by the PI
Exclusion Criteria:
- Intractable epilepsy not responsive to anticonvulsive therapy in the patient with this syndrome.
- History of prior drug intolerances/drug hypersensitivity to any agent that may be similar to L Dopa .
- Progressively deteriorating EEG pattern.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Sinemet
The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa.
The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day.
The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
|
The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa.
The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day.
The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in motor control determined through composite measure- Tremor
Time Frame: 2 years
|
Documented improvement in motor control including tremor using SARA Scale ( Short Ataxia Rating Assesment)
|
2 years
|
Improvement in motor control determined through composite measure-Ataxia
Time Frame: 2 years
|
Documented improvement in motor control including ataxia, using SARA Scale ( Short Ataxia Rating Assesment)
|
2 years
|
Improvement in motor control determined through composite measure- SARA score
Time Frame: 2 years
|
Documented improvement in SARA score
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in development determined through composite measure-Psychoeducational Testing
Time Frame: 2 years
|
Documented improvement in development based upon Bailey, Denver, Vanderbilt, Educational testing.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bennett Lavenstein, MD, Children's National Health System, Department of Neurology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Movement Disorders
- Abnormalities, Multiple
- Chromosome Disorders
- Syndrome
- Angelman Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Levodopa
Other Study ID Numbers
- IRB PRO00004116
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angelman Syndrome
-
Ovid Therapeutics Inc.CompletedPrimary Disease or Condition Being Studied: Angelman Syndrome (AS)United States, Australia, Germany, Israel, Netherlands
-
University of OxfordHoffmann-La Roche; Foundation for Angelman Syndrome Therapeutics UKRecruiting
-
Fondazione per la Ricerca Ospedale MaggioreCompleted
-
Ovid Therapeutics Inc.CompletedAngelman SyndromeUnited States, Israel
-
Boston Children's HospitalCompletedAngelman SyndromeUnited States
-
Foundation for Angelman Syndrome Therapeutics,...Queensland University of TechnologyRecruiting
-
The Emmes Company, LLCBoston Children's Hospital; Ionis Pharmaceuticals, Inc.CompletedAngelman SyndromeUnited States
-
Puerta de Hierro University HospitalParc Taulí Hospital UniversitariRecruiting
-
Hoffmann-La RocheActive, not recruitingAngelman SyndromeUnited States, Spain, Netherlands, Italy
Clinical Trials on Levodopa
-
University Hospital, GenevaRecruitingParkinson DiseaseSwitzerland
-
IRCCS San RaffaeleAgenzia Italiana del FarmacoCompleted
-
Newron Pharmaceuticals SPACompletedIdiopathic Parkinson's DiseaseItaly
-
Rush University Medical CenterCompletedParkinson DiseaseUnited States
-
University of MinnesotaNot yet recruitingIdiopathic Parkinson DiseaseUnited States
-
Seoul National University HospitalSamsung Medical Center; SMG-SNU Boramae Medical CenterCompletedParkinson DiseaseKorea, Republic of
-
Orion Corporation, Orion PharmaCompletedParkinson's DiseaseFinland, Germany, Hungary, Latvia
-
AbbVie (prior sponsor, Abbott)Completed
-
NeuroDerm Ltd.Quotient ClinicalCompletedParkinson's DiseaseUnited Kingdom
-
Snyder, Robert W., M.D., Ph.D., P.C.WithdrawnAge-related Macular DegenerationUnited States